Effects of Lysophosphatidic Acid on the Migrations of Hepatoma Cells with Different Metastasis

Abstract

Abstract: The aim of this study is to investigate the effect of lysophosphatidic acid（LPA）on cell migration of two kinds of hepatocellular carcinoma cells（MHCC97H and HepG2）with different metastasis，and to evaluate the underlying mechanism. Transwell assay was employed to investigate the impact of LPA on the migration of the hepatocellular carcinoma cells，and RT-PCR to detect the mRNA expression of LPA receptor（LPAR）in the hepatocellular carcinoma cells. Results showed that the LPA presented no obvious effect on the migration of HepG2 cells in low metastasis，but significantly promoted the migration of MHCC97H cells in high metastasis. LPA caused insignificant impact to the proliferation of both cells. RT-PCR demonstrated that expressions of LPAR at mRNA level in MHCC97H and HepG2 cells were different，LPAR1 expressed in MHCC97H cells，however，not in HepG2 cells. Importantly，the promotion effect of LPA on the migration of MHCC97H cells disappeared after Ki16425（a specific inhibitor of LPAR1/3）was used to block the role of LPAR1 in MHCC97H cells. This indicated that LPA promoted MHCC97H cell migration via interaction with LPAR1. The effects of LPA on the migration of hepatoma cells in different metastasis varied，which resulted from the different expressions of LPAR in these two cell types.

Key words: lysophosphatidic acid, hepatoma cell, lysophosphatidic acid receptor, cell migration

CLC Number:

10.13560/j.cnki.biotech.bull.1985.2016.12.029

LI Duo,LI Jia-wen,YUAN Qun-chen,LIN Chuan-chuan,SONG Guan-bin. Effects of Lysophosphatidic Acid on the Migrations of Hepatoma Cells with Different Metastasis[J]. Biotechnology Bulletin, 2016, 32(12): 189-194.

References

[1] Ahmedin J, Freddie B, Center MM, et al. Global cancer statistics[J] . Ca Cancer J Clin, 2011, 61（2）：69-90.
[2] Sun J, Luo Q, Liu L, et al. Biomechanical profile of cancer stem-like cells derived from MHCC97H cell lines[J] . J Biomech, 2016, 49（1）：45-52.
[3] Bhattacharya S, Darjatmoko SR, Polans AS, et al. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB[J] . Melanoma Res, 2011, 21（3）：180-187.
[4] Luo Z, Wang Q, Lau WB, et al. Tumor microenvironment：the culprit for ovarian cancer metastasis[J] . Cancer Lett, 2016, 377（2）：174-182.
[5] Liona-Minguez S, Ghasssemian A, Helleday T. Lysophosphatidic acid receptor（LPAR）modulators：the current pharmacological toolbox[J] . Prog Lipid Res, 2015, 58：51-75.
[6] Liu Y, An S, Ward R, et al. G protein-coupled receptors as promising cancer targets[J] . Cancer Lett, 2016, 376（2）：226-239.
[7] Leblanc R, Peyruchaud O. New insights into the autotoxin/LPA axis in cancer development and metastasis[J] . Exp Cell Res, 2015, 333（2）：183-189.
[8] Celine P, Simon O, Saulnier-Blache B. Lysophosphatidic acid synthesis and release[J] . Prostaglandins, 2001, 64（1-4）：1-10.
[9] Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer[J] . Nat Rev Cancer, 2003, 3（8）：582-591.
[10] Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1[J] . Cancer Res, 2003, 63（7）：1706-1711.
[11] Du J, Sun C, Hu Z, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling[J] . PLoS One, 2010, 5（12）：e15940.
[12] Willier S, Butt E, Grunewald TG. Lysophosphatidic acid（LPA）signalling in cell migration and cancer invasion：a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays[J] . Biol Cell, 2013, 105（8）：317-33.
[13] Herrema H, Czajkowska D, Theard D, et al. Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells[J] . Mol Biol Cell, 2006, 17（7）：3291-3303.
[14] Ji WC, Herr DR, Noguchi K, et al. LPA receptors：subtypes and biological actions[J] . Annu Rev Pharmacol Toxicol, 2010, 50（1）：157-86.
[15] Guo R, Kasbohm EA, Arora P, et al. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells[J] . Endocrinology, 2006, 147（10）：4883-4892.
[16] Park SY, Jeong KJ, Panupinthu N, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression[J] . Oncogene, 2011, 30（11）：1351-1359.
[17] Hao F, Tan M, Xu X, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA1, p42 and p38α[J] . Biochim Biophys Acta, 2007, 1771（7）：883-892.
[18] Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1[J] . J Biol Chem, 2004, 279（8）：6595-6605.
[19] Komachi M, Tomura H, Malchinkhuu E, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites[J] . Carcinogenesis, 2009, 30（3）：457-465.
[20] Kato K, Yoshikawa K, Tanabe E, et al. Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells[J] . Tumour Biol, 2013, 33（5）：1739-1744.
[21] Yamada T, Yano S, Oqino H, et al. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2[J] . Cancer Sci, 2008, 99（8）：1603-1610.
[22] Sokolov E, Eheim AL, Ahrens WA, et al. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma[J] . J Surg Res, 2013, 180（1）：104-113.